KKRC
UTHR icon

Kohlberg Kravis Roberts & Co’s United Therapeutics UTHR Stock Holding History

Kohlberg Kravis Roberts & Co’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-27,500
Closed -$3.72M – 55
2017
Q1 		$3.72M Hold
27,500
– – 0.07% 42
2016
Q4 		$3.94M Hold
27,500
– – 0.06% 39
2016
Q3 		$3.25M Buy
+27,500
New +$3.3M 0.04% 44

Other funds holding UTHR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Kohlberg Kravis Roberts & Co's UTHR Position: Q2 2017 in Review

Kohlberg Kravis Roberts & Co sold out of United Therapeutics (UTHR) in Q2 2017, closing a stake of 27,500 shares — an estimated $3.72M sold.

Kohlberg Kravis Roberts & Co first reported a position in UTHR in Q3 2016 and held it in 3 quarters. The position peaked at $3.94M in Q4 2016. 373 funds tracked by Wall St. Rank hold UTHR as of Q2 2017.

  • Kohlberg Kravis Roberts & Co reported no remaining United Therapeutics position as of Q2 2017 after selling out during the quarter.
  • Kohlberg Kravis Roberts & Co sold 27,500 United Therapeutics shares in Q2 2017, an estimated $3.72M.
  • Kohlberg Kravis Roberts & Co first reported a position in United Therapeutics in Q3 2016 and held it in 3 quarters.
  • Kohlberg Kravis Roberts & Co's United Therapeutics position peaked at $3.94M in Q4 2016.
  • 373 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2017.

Based on Kohlberg Kravis Roberts & Co's 13F filing for Q2 2017, filed 14 Aug 2017.